0.6820USD-0.99%Mkt Cap: 63.41M $P/E: —1d ago
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed…
Industry Peers
Drug Manufacturers - Specialty & GenericIndicators:|
Key Statistics
Company
Market Cap63.41M $
Enterprise Value65.21M $
Revenue (TTM)5.61M $
Gross Profit4.49M $
Net Income (TTM)-24.76M $
Revenue/Share0.0670 USD
Last Price0.6820 USD
Fiscal Year EndSep 2025
MR QuarterMar 2026
Employees—
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue11.62
P/S11.30
P/B1.80
EPS (TTM)-0.48
EPS (Forward)—
52W Range
0.49108% of range2.840
52W High2.840 USD
52W Low0.4910 USD
Profitability
Gross Margin80.07%
Oper. Margin-1716.17%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-55.19%
ROA-24.53%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.49M $
CapEx (TTM)5.75M $
FCF Margin-420.87%
FCF Yield-37.24%
Net Debt1.17M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.08
Current Ratio0.50
Quick Ratio0.06
Book Value/Sh0.3790 USD
Cash/Share0.0280 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)4.000 USD
Upside (mean)+486.5%
Target Range4.000 USD – 4.000 USD
# Analysts1
Ownership
Shares Out.92.98M
Float17.72M
Insiders77.51%
Institutions15.32%
Short Interest
Short Ratio7.5d
Short % Float2.70%
Short % Out.0.49%
Shares Short453.35K
Short (prev mo.)631.73K
Technical
SMA 500.7739 (-11.9%)
SMA 2001.078 (-36.7%)
Beta3.48
S&P 52W Chg20.25%
Avg Vol (30d)37.15K
Avg Vol (10d)46.77K
Technical Indicators
RSI (14)46.2
MACD-0.0187
MACD Signal-0.0244
MACD Hist.+0.0057
BB Upper0.7328 USD
BB Middle0.6816 USD
BB Lower0.6304 USD
BB Width15.02%
ATR (14)0.0511 USD
Vol Ratio (20d)0.06x